BioCentury
ARTICLE | Clinical News

Aimspro regulatory update

June 8, 2009 7:00 AM UTC

Daval said the Australian Therapeutic Goods Administration (TGA) granted Orphan Drug designation for Aimspro to treat amyotrophic lateral sclerosis (ALS). The anti-inflammatory agent derived from hype...